CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 411 enrolled
Drug / intervention
bictegravir/emtricitabine/tenofovir alafenamidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03789968
NCT03789968N/ACompleted
CompareCT.gov

The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients

Thomas Jefferson University·observational·Posted Dec 31, 2018·Updated Oct 8, 2020

In Brief

An observational study evaluating bictegravir/emtricitabine/tenofovir alafenamide for HIV/AIDS. Completed, enrolled 411 participants across 1 site.

Detailed Summary

This study will assess changes in the incidence and severity of drug interactions before and after switching antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide-based regimens in treatment experienced patients living with HIV infection.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV/AIDS
CountriesUnited States
CollaboratorsUniversity of Maryland, College Park, Indiana University Health, The Brooklyn Hospital Center, University of Illinois at Chicago, Nova Southeastern University, University of California, San Francisco

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedDec 31, 2018
Enrollment StartSep 1, 2019
Primary CompletionSep 5, 2020
Study CompletionOct 5, 2020
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.5 years ago

Interventions

bictegravir/emtricitabine/tenofovir alafenamidedrug

Treatment experienced patients with HIV infection that switched to a bictegravir/emtricitabine/tenofovir alafenamide-based ART regimen